Phosphodiesterase 4 Inhibitors

"Phosphodiesterase 4 Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that specifically inhibit PHOSPHODIESTERASE 4.

Descriptor ID	D058988
MeSH Number(s)	D27.505.519.389.735.374
Concept/Terms	Phosphodiesterase 4 Inhibitors Phosphodiesterase 4 Inhibitors Inhibitors, Phosphodiesterase 4 PDE4 Inhibitors Inhibitors, PDE4 Phosphodiesterase Type 4 Inhibitors PDE-4 Inhibitors Inhibitors, PDE-4 PDE 4 Inhibitors

Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase 4 Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Phosphodiesterase Inhibitors [D27.505.519.389.735]
Phosphodiesterase 4 Inhibitors [D27.505.519.389.735.374]

Below are MeSH descriptors whose meaning is related to "Phosphodiesterase 4 Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase 4 Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Phosphodiesterase 4 Inhibitors" by people in this website by year, and whether "Phosphodiesterase 4 Inhibitors" was a major or minor topic of these publications.

Bar chart showing 13 publications over 10 distinct years, with a maximum of 2 publications in 2009 and 2013 and 2025

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	1	1	2
2011	1	0	1
2012	1	0	1
2013	2	0	2
2014	1	0	1
2015	1	0	1
2016	1	0	1
2017	1	0	1
2020	1	0	1
2025	2	0	2

Below are the most recent publications written about "Phosphodiesterase 4 Inhibitors" by people in Profiles.

Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2203-2214.

View in: PubMed
Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025 Jun 12; 392(22):2193-2202.

View in: PubMed
Nicolas SE, Bear MD, Kanaan AO, Coman OA, Dima L. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. Am J Ther. 2023 Nov-Dec 01; 30(6):e535-e542.

View in: PubMed
Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020 Feb 10; 21(1):47.

View in: PubMed
Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017 07; 50(1).

View in: PubMed
Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting ?2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Int J Chron Obstruct Pulmon Dis. 2016; 11:1921-8.

View in: PubMed
Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016 Jun; 75(6):1065-73.

View in: PubMed
Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015 Mar 07; 385(9971):857-66.

View in: PubMed
Wedzicha JA, Rabe KF, Martinez FJ, Bredenbr?ker D, Brose M, Goehring UM, Calverley PMA. Response. Chest. 2014 Feb; 145(2):428.

View in: PubMed
Yu T, Fain K, Boyd CM, Singh S, Weiss CO, Li T, Varadhan R, Puhan MA. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014 Jul; 69(7):616-22.

View in: PubMed

People

Explore

Similar Concepts

Top Journals